Prostate | Breast | Melanoma | Colorectal | NHL | Lung | Kidney | Uterus | Bladder | Leukaemia | Thyroid | Multiple myeloma | Oesophagus | Other cancer | Any cancer | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | 5854 | 4330 | 3398 | 3011 | 814 | 493 | 486 | 479 | 398 | 376 | 338 | 183 | 83 | 2262 | 22,505 |
Median time since diagnosis (years) | 3.4 | 4.9 | 4.5 | 3.8 | 3.6 | 2.1 | 4.0 | 4.0 | 4.4 | 3.7 | 4.0 | 2.9 | 2.2 | 3.7 | 3.9 |
Time since diagnosis (years) | |||||||||||||||
< 1 | 16.2% | 10.3% | 12.7% | 16.6% | 15.6% | 29.8% | 14.8% | 15.5% | 14.1% | 16.8% | 16.6% | 17.5% | 38.6% | 16.8% | 15.0% |
1 to < 5 | 50.1% | 41.0% | 42.6% | 43.7% | 45.1% | 45.6% | 44.0% | 41.5% | 41.5% | 48.4% | 42.6% | 59.6% | 36.1% | 44.7% | 45.0% |
5 to < 10 | 27.2% | 37.6% | 34.6% | 31.5% | 31.7% | 22.1% | 32.5% | 34.0% | 36.7% | 29.0% | 32.3% | 20.8% | 24.1% | 29.5% | 31.7% |
10 or more | 6.5% | 11.1% | 10.1% | 8.2% | 7.6% | 2.4% | 8.6% | 9.0% | 7.8% | 5.9% | 8.6% | 2.2% | 1.2% | 8.9% | 8.4% |
Stage | |||||||||||||||
localised to tissue or origin | 56.2% | 59.6% | 88.9% | 41.1% | N/A | 43.6% | 74.9% | 64.7% | 54.0% | N/A | 67.5% | N/A | 49.4% | 38.5% | 55.6% |
regional spread, adjacent organs and/or regional lymph nodes | 6.7% | 32.4% | 4.5% | 45.3% | N/A | 25.4% | 14.6% | 21.3% | 10.3% | N/A | 15.4% | 27.7% | 22.7% | 18.9% | |
distant metastases | 0.7% | 2.3% | 1.3% | 5.1% | N/A | 13.4% | 2.3% | 3.8% | 2.0% | N/A | 3.0% | N/A | 4.8% | 10.2% | 3.1% |
unknown | 36.5% | 5.7% | 5.2% | 8.6% | N/A | 17.7% | 8.2% | 10.2% | 33.7% | N/A | 14.2% | N/A | 18.1% | 28.6% | 22.5% |
Recent treatment | |||||||||||||||
No | 78.7% | 71.5% | 92.9% | 80.1% | 73.8% | 64.9% | 87.0% | 87.3% | 81.2% | 70.7% | 85.2% | 35.0% | 65.1% | 78.4% | 79.1% |
Yes | 21.3% | 28.5% | 7.1% | 19.9% | 26.2% | 35.1% | 13.0% | 12.7% | 18.8% | 29.3% | 14.8% | 65.0% | 34.9% | 21.6% | 20.9% |